• Small Molecules
    • Biologics
    • Other Drug Modalities
    • SynVent Integrated Drug Discovery
      • SynVent Integrated Drug Discovery

        SynVent is Syngene’s platform for fully integrated therapeutic discovery and development across large and small molecules. 

    • Industries
    • Emerging Biopharma
      • Emerging Biopharma

        Emerging biopharma work at the forefront of science, often venturing into disease areas where little or no real-world data exists to work with or regulatory frameworks to work within.

    • Dedicated Centers
      • Dedicated Centers

        Our Dedicated Centers offer dedicated multi-disciplinary scientific teams, support personnel, and a tailormade ring-fenced and fire-walled infrastructure as per client specifications to support their  R&D  goals

    • Center for Advanced Protein Studies (CAPS)
      • Center for Advanced Protein Studies (CAPS)

        Centre for Advanced Protein Studies [CAPS] is a state-of-the-art advanced national facility located in the Syngene campus, Bangalore.

  • Careers

Who we are

We are an innovation-led contract research, development and manufacturing organization offering integrated scientific services from early discovery to commercial supply.

What we do

We offer clients a customized end-to-end solution to fulfil their R&D and manufacturing requirements. Our approach enables us to forge client relationships that move beyond the traditional service outsourcing model into true end-to-end collaborations.

Discovery

Our Discovery Services span the entire spectrum of early stage research from target …

Development

Our Development Services encompass activities from pre-clinical to clinical trials…

Manufacturing

Our Manufacturing services include cGMP-compliant facilities for clinical supplies, registration batches…

Dedicated Centers

Our Dedicated Centers offer dedicated multi-disciplinary scientific teams, support…

InstaVisit – Visit Syngene virtually

Syngene InstaVisit is an interactive virtual experience designed to give you a 360 degree view of Syngene’s world-class facilities and capabilities. The platform allows you to change your perspective, look around and zoom in as we take you on a guided tour of Syngene’s labs.

Visit Syngene virtually with a 360 degree view of Syngene’s world-class facilities and capabilities
0 +

Active Clients

0

Collaborations with top 20 Pharma/Biotech companies

5200

Scientists

0

Mn sq. ft. of R&D and manufacturing infrastructure

0 +

Patents 

Syngene named one of the ‘World’s Most Sustainable Companies 2025’ by TIME Magazine & Statista

Press Release
3rd Jul, 2025

Strategic shifts position India as a pharma partner of choice

News
1st Jul, 2025

India enjoys a far greater degree of confidence in IP security for Western partners than does China

News
30th Jun, 2025

Overcoming ADME Challenges in PROTAC Development: Key Insights from Syngene Experts

Targeted protein degraders like PROTACs offer novel therapeutic potential but face ADME hurdles—poor solubility, permeability, and weak IVIVC. Experts Prasoon Chaturvedi (C4 Therapeutics), Vishwottam Kandikere, and Amol Raje (Syngene) discussed solutions.

Bridging the Unbridgeable: The Promise of PROTACs in Drug Discovery

Imagine a world where diseases once deemed “undruggable” are met with targeted, precise therapies. This vision is rapidly becoming a reality, thanks to the revolutionary technology of PROTACs (proteolysis-targeting chimeras).

Paws, Pills and Progress – CRDMO’s pivotal role

As I stepped into the conference hall in Boston, I overheard an investor say, “The next billion-dollar biotech might just come from the animal health sector.

Upcoming events

July 9th-11th
Tokyo
July 16th-18th
Kuala Lampur
July 18th-22nd
Washington
July 24th-27th
Taiwan
July 29th-31st
Georgia
August 11th-13th
Philadelphia

Corporate Social Responsibility

To strive towards developing and sustaining healthy and empowered communities by improving the quality of life.

Governance

Behind consistent growth is good governance

Careers

Discover a world of opportunities

Annual Reports

Touching a billon lives through innnovation

To view or email, Please share your details view

Your browser does not support this function.

To download, Please share your details

To view or email, Please share your details view

To download, Please share your details